Disease management in the treatment of patients with chronic heart failure who have universal access to health care: a randomized controlled trial

Autor: Dov Freimark, Barbara G. Silverman, Arnona Ziv, Shlomi Matetzky, Dorit Goldman, Ofra Kalter-Leibovici, Avishay Grupper, Havi Murad, Michal Benderly, Elad Asher, Mordechai Shani, Tali Cukierman-Yaffe, Galit Kaufman, Nurit Friedman, Laurence S. Freedman, Haim Silber, Miriam Amitai
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Zdroj: BMC Medicine, Vol 15, Iss 1, Pp 1-13 (2017)
BMC Medicine
ISSN: 1741-7015
DOI: 10.1186/s12916-017-0855-z
Popis: Background The efficacy of disease management programs in improving the outcome of heart failure patients remains uncertain and may vary across health systems. This study explores whether a countrywide disease management program is superior to usual care in reducing adverse health outcomes and improving well-being among community-dwelling adult patients with moderate-to-severe chronic heart failure who have universal access to advanced health-care services and technologies. Methods In this multicenter open-label trial, 1,360 patients recruited after hospitalization for heart failure exacerbation (38%) or from the community (62%) were randomly assigned to either disease management or usual care. Disease management, delivered by multi-disciplinary teams, included coordination of care, patient education, monitoring disease symptoms and patient adherence to medication regimen, titration of drug therapy, and home tele-monitoring of body weight, blood pressure and heart rate. Patients assigned to usual care were treated by primary care practitioners and consultant cardiologists. The primary composite endpoint was the time elapsed till first hospital admission for heart failure exacerbation or death from any cause. Secondary endpoints included the number of all hospital admissions, health-related quality of life and depression during follow-up. Intention-to-treat comparisons between treatments were adjusted for baseline patient data and study center. Results During the follow-up, 388 (56.9%) patients assigned to disease management and 387 (57.1%) assigned to usual care had a primary endpoint event. The median (range) time elapsed until the primary endpoint event or end of study was 2.0 (0–5.0) years among patients assigned to disease management, and 1.8 (0–5.0) years among patients assigned to usual care (adjusted hazard ratio, 0.908; 95% confidence interval, 0.788 to 1.047). Hospital admissions were mostly (70%) unrelated to heart failure. Patients assigned to disease management had a better health-related quality of life and a lower depression score during follow-up. Conclusions This comprehensive disease management intervention was not superior to usual care with respect to the primary composite endpoint, but it improved health-related quality of life and depression. A disease-centered approach may not suffice to make a significant impact on hospital admissions and mortality in patients with chronic heart failure who have universal access to health care. Clinical trial registration Clinicaltrials.gov identifier: NCT00533013. Trial registration date: 9 August 2007. Initial protocol release date: 20 September 2007. Electronic supplementary material The online version of this article (doi:10.1186/s12916-017-0855-z) contains supplementary material, which is available to authorized users.
Databáze: OpenAIRE
Externí odkaz: